2005 - 2003 Press releases
Clavis Pharma announces inclusion of first patient in Phase II study with the novel cancer drug ELACYT
Clavis Pharma, a biopharmaceutical company focusing on the development of improved cancer therapeutics, today announced that the first patient has been included in the first Phase II study with its lead drug candidate, ELACYTTM.
Clavis Pharma announces IND approval for Phase II with the novel cancer drug ELACYT™
Clavis Pharma, a biopharmaceutical company focusing on the development of improved cancer therapeutics, today announced that the United States Food and Drug Administration (FDA) ...
Clavis Pharma achieves European Approval of broad platform patent for Lipid Vector Technology
Clavis Pharma, a biopharmaceutical company focusing on the development of improved cancer therapeutics, today announced the issuance of the European patent EP ...
Clavis Pharma's anti-cancer drug CP-4055 shows promise of efficacy in successful Phase I clinical study
Clavis Pharma AS announced today that it has completed a Phase I clinical study of its lead anti-cancer agent CP-4055 in patients with advanced cancer.
Clavis Pharma Initiates Phase I/II Clinical Trial with Novel Anticancer Agent for the Treatment of Solid Tumours
Clavis Pharma AS (formerly ConPharma As) today announced that its most advanced compound, CP-4055, has entered Phase I/II clinical trials for the treatment of ...
